Background. The use of biomarkers that allow early therapeutic intervention or intensive follow-up evaluation is expected to be a powerful means for reducing breast cancer mortality. MicroRNAs (miRNAs) are known to play major roles in cancer biology including metastasis. This study aimed to develop a novel miRNA risk score to predict patient survival and metastasis in breast cancer.
ABSTRACT
Background. The use of biomarkers that allow early therapeutic intervention or intensive follow-up evaluation is expected to be a powerful means for reducing breast cancer mortality. MicroRNAs (miRNAs) are known to play major roles in cancer biology including metastasis. This study aimed to develop a novel miRNA risk score to predict patient survival and metastasis in breast cancer.
Methods. An integrated unbiased approach was applied to derive a composite risk score for prognosis based on miRNA expression in primary breast tumors in 1051 breast cancer patients from The Cancer Genome Atlas (TCGA). Further analysis of the risk score with metastasis/ recurrence was performed using the TCGA data set and validated in a separate patient population using small RNA sequencing.
Results. The three-miRNAs risk score (miR-19a, miR-93, and miR-106a) was developed using the TCGA cohort, which predicted poor prognosis (p = 0.0005) independently of known clinical risk factors. The prognostic value was validated in another three following independent cohorts: GSE19536 (p = 0.0009), GSE22220 (p = 0.0003), and the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) (p = 0.0023). The three-miRNAs risk score predicted bone recurrence in TCGA (p = 0.0052), and the findings were validated in another independent population of patients who experienced bone recurrence and age/stage-matched patients without any recurrence. The three-miRNAs risk score enriched multiple metastasis-related gene sets such as angiogenesis and epithelial mesenchymal transition in a geneset-enrichment analysis. Conclusions. The authors developed the novel miRNAbased risk score, which is a promising biomarker for prediction of worse survival and bone recurrence potential in breast cancer.
Intrinsic subtype classification using gene expression microarray has revolutionized the way we understand breast cancer. 1 Differences across breast cancer subtypes in response to different treatments and prognosis currently are well established. [1] [2] [3] Targeted therapy based on each patient's unique cancer biology in conjunction with a more rational use of cytotoxic systemic therapy has contributed to the decreasing mortality rate for breast cancer during recent decades in the United States. However, more than 40,000 women still die of breast cancer every year in the United States alone, 4, 5 highlighting the need for a deeper understanding of breast cancer biology for further improvement of treatment.
Breast cancer intrinsic subtypes were first discovered based primarily on the expression profile of coding genes, which predated our current appreciation of the versatile roles played by non-coding RNAs, such as long non-coding RNA and microRNA (miRNA), which impact almost every aspect of cancer, from etiology to progression and response to treatment.
A class of small non-coding RNA, miRNAs constitute an important epigenetic mechanism fine-tuning the transcription and translation of protein-coding genes. Since its discovery, 6 ,7 dysregulated miRNA expression has been identified in various cancers including breast cancer. [8] [9] [10] [11] [12] [13] The primary aims of the current study were to evaluate the prognostic value of miRNA expression profiles of primary breast cancer and to develop an miRNA-based risk score for patient prognosis. Three available public data sets were used: The Cancer Genome Atlas (TCGA), the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC), and the Gene Expression Omnibus (GEO).
Our integrated and unbiased approach identified a composite score based on three miRNAs from primary breast cancer that are significantly associated with poor prognosis. We also found that this score was associated with enrichment of metastasis-related gene sets and can be used to predict bone recurrence in breast cancer patients.
MATERIALS AND METHODS

Patient Populations
Both miRNAs and RNA expression data with linked clinical data were available for 2580 breast cancer cases from TCGA (n = 1051), 14 METABRIC (n = 1223), 15, 16 and two GEO data sets (GEO22220: n = 210; GEO19536: n = 96). 17, 18 The study used TCGA as the discovery cohort and the other three as validation cohorts. The patient demographics of those cohorts are summarized in Tables S1  and S2 . In all the data sets, breast cancer subtypes were classified according to immunohistochemistry markers. 19, 20 For TCGA data, because PAM50 subtype classification was not publically available from all breast tumors from University California Santa Cruz Xena (UCSC Xena) (htt ps://xena.ucsc.edu/public-hubs/), the ''genefu'' package 21 was applied to classify all 1051 samples in the cohort, which uses the same algorithm as TCGA.
Development of an miRNA-Based Risk Score
Among the 1051 breast cancer patients who had microRNA expression data and required clinical information registered in the TCGA data set, two subsets of patients were defined based on overall survival (OS) status: a long-survival group (those who survived longer than 5 years after diagnosis, n = 240) and a short-survival group (those deceased within 3 years after diagnosis, n = 65). To emphasize the biologic feature that could have an impact on patient survival, we used these two subsets (long survival and short survival) for initial development of the miRNA-based risk score.
We identified 1881 miRNAs annotated in the TCGA data set, and after excluding those with low miRNA counts, 1549 miRNAs were analyzed for the developmental settings. Differentially expressed miRNAs between the two groups were identified using DEseq2 (Differential expression analysis for sequence count data; http://www-huber.e mbl.de/users/anders/DESeq/) based on the negative binomial distribution. 22 Of the top 19 miRNAs (miR-103a-1, miR-103a-2, miR-93, miR-92a-1, miR-92a-2, miR-1307, miR-17, miR-196b, miR-20a, miR-500a, miR-128-2, miR19b-1, miR-19b-2, miR-20b, miR-106a, miR-19a, miR-660, miR-184, and miR-187) identified after adjustment for multiple comparisons (adjusted p value\ 0.1), one miRNA (mir-103a-2, mir-92a-2, mir-19b-1, miR-19b-2, or miR-17) was randomly dropped from highly correlated pairs (r 2 [ 0.85) to reduce multicollinearity and improve stability for further model selection. Stepwise selection then was used to select three miRNAs (miR-19a, miR-93, and miR-106a) in a final multivariable model based on the Akaike information criterion (AIC). Details are presented in Supplementary File S1. A composite risk score based on the three miRNAs was derived as a weighted linear combination of their expression levels.
Patients were subsequently dichotomized into low-and high-risk groups based on the risk score. To determine an optimal cutoff point, a series of candidate points were evaluated in Cox proportional hazard models, 23 and the final cutoff was chosen based on model significance. [24] [25] [26] [27] The same classification method based on the miRNA risk score was applied to the three independent validation data sets from METABRIC 15, 16 and GEO. 17, 18 To test whether the prognostic value of the risk score was independent of tumor histopathologic characteristics, tumor stage (according to the tumor-node-metastasis [TNM] classification of the American Joint Committee on Cancer [AJCC] 7th ed), 20 estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status were adjusted in a multivariable model.
Identification of Subtypes Using the Prosigna Breast
Cancer Prognostic Gene Signature Assay (PAM50) Gene Signature in the TCGA Cohort To classify all the TCGA patients into subtypes defined by PAM50 gene signature, we established a novel computational algorithm. The PAM50 subtypes were called using the Bioconductor genefu package and gene expression using RNA-sequencing data of the TCGA breast cancer primary solid tumor samples retrieved from Broad Institute Firehose (https://gdac.broadinstitute.org/). The subsequent classification was mostly consistent with the PAM50 calls made by the TCGA Analysis Working Group (AWG), retrieved from the XENA browser (https://xenabrowser.net/).
Validation Study of the miRNA-Based Risk Score With Bone Metastasis Using Small RNA-Sequencing
For an independent validation of the prognostic value that the miRNA-based risk score has for bone metastasis, fresh frozen primary tumors were obtained from age-and stage-matched breast cancer patients from the Roswell Park Cancer Institute Pathology Network Shared Resource (patient details not shown). The bone recurrence group (n = 10) consisted of patients who eventually experienced bone recurrence at an initial metastatic site during the follow-up period, and the control breast cancer group (n = 10) comprised patients who had no tumor recurrence for at least for 5 years after primary tumor resection.
Two pathologists independently evaluated all samples and confirmed that they included more than 80% of the neoplastic cell component. Total and small RNAs were isolated using the miRNeasy mini kit (Qiagen, Germantown, MD, USA) as per manufacturer recommendations. The small RNA-sequencing libraries were prepared with the TruSeq Small RNA kit (Illumina Inc, San Diego, CA, USA) from a total RNA of 1 lg. Validated libraries were pooled with equal molar value in the final concentration and sequenced using the Illumina HiSeq 2500 with 50-cycle single-read sequencing (Illumina, Inc.). The miRNA expression level was normalized, and log2 was transformed using the DEseq2 package. Ridge regression was used to derive a score for these samples based on the expression levels of the same three miRNAs, and the predicting performance for bone metastatic status was evaluated using area under the curve (AUC) analysis. 28 The study was approved by the Institutional Review Board of Roswell Park Cancer Institute for human subject protection.
Statistical Analysis
All statistical analyses were performed using R software and Bioconductor (https://www.r-project.org/). In the TCGA and GEO cohorts, OS was defined as the time from the date of diagnosis to the date of death by any cause. In the METABRIC cohort, disease-specific survival (DSS) was defined as the time from the date of diagnosis to the date of death by a cancer-specific cause. Disease-free survival (DFS) was defined as the time from the date of diagnosis to the date of relapse.
To compare the survival curves between subgroups, the Kaplan-Meier method with the log-rank test was used. As we previously reported, Cox proportional hazard models were used for multivariable analysis to derive hazard ratios (HRs) and 95% confidence intervals (CIs), and the proportional hazard assumption was tested using Schoenfeld residuals. [24] [25] [26] [27] 29, 30 Cumulative incidence functions (CIFs) were estimated to assess the probability of metastases to different sites and tested for statistical significance in the TCGA cohort. Gene set enrichment analysis (GSEA) was performed using software provided by the Broad Institute (http://software.broadinstitute.org/gsea/index.jsp). 31 In all analysis, a two-sided p value lower than 0.05 was considered statistically significant, unless otherwise specified. This ''prognostic marker'' study was conducted according to the REMARK guidelines. 32 
RESULTS
Development of an miRNA-Based Risk Score for Breast Cancer Prognosis in TCGA
The overall study design is shown in Fig. 1 . We initially identified 19 miRNAs that were most differentially expressed between the long-and short-survival groups (BH fdr \ 0.1 after adjustment for multiple comparison) (Fig. S1 , Tables S3 and S4). After removal of five miRNAs from clusters in which miRNAs were highly correlated, stepwise selection retained three miRNAs (miR-19a, miR-93, and miR-106a) in the final multivariable model. More details can be seen in the Supplementary file. A high miRNA-based risk score using the expression of these three miRNAs was associated with poor survival of breast cancer patients, with a minimum p value among the two distinct groups. When the miRNA-based scores were calculated for all the TCGA patients (n = 1051), the group with the high miRNA-based score had a significantly shorter OS (HR, 2.62; 95% CI, 1.53-4.49; p = 0.0005) and DFS (HR, 2.51; 95% CI, 1.54-4.10; p = 0.0002) (Fig. 2a, b ) than the group with the low score.
Validation of an miRNA-Based Risk Score in the METABRIC and GEO Data Sets
Consistently across all three validation cohorts, the patients with the high score had a significantly poorer overall survival than those with the low score in the METABRIC (p = 0.0023), GSE19536 (p = 0.0009), and GSE22220 cohorts (p = 0.0003) (Fig. 2c-e) .
Independence of the miRNA-Based Risk Score From Known Breast Cancer Prognostic Markers
The miRNA-based risk score was not associated with any known breast cancer prognostic markers in TCGA, including the PAM50 subtype (Table S5 ). The METAB-RIC patients with the high risk score tended to have tumors of advanced tumor stage, ER/PR negativity, HER2 positivity, and triple-negative breast cancer (TNBC) subtype (p \ 0.01) (Table S5) . Regardless, adjustment for those prognostic markers in multivariable models did not substantially change the associations of OS with the miRNAbased risk score in either the TCGA cohort or the METABRIC cohort (Table 1 ). In further subgroup analyses stratified by ER, PR, or HER2, no apparent difference in the associations of OS with the risk score was observed in TCGA (Fig. S2) .
We also performed stratified prognostic analysis of the miRNAs score using PAM50, which classified TCGA samples into the major breast cancer subtypes. All breast cancers in TCGA were divided into three representative populations (luminal A or B or normal-like, HER2-enriched, and basal-like) using the PAM50 analysis. 33 Although there was no significant separation of distribution by subtype based on the three miRNA scores with corresponding analysis of the tumors from 1051 patient samples in TCGA (Fig. 3a, Table S6 ), the patients who had the luminal A or B and normal-like subtype with a high miRNA score had significantly worse OS (p = 0.0300) and DFS (p = 0.0098) in contrast to the basal-like and HER2-enriched populations (Fig. 3b, c, Fig. S2 ). Together, even after stratification by tumor stage or PAM50 subtype, the prognostic value of the risk score appeared limited to patients with stage 2 or higher disease or those with the luminal A, luminal B, and normal-like subtypes.
High miRNA-Based Risk Score of Primary Breast Tumors Significantly Associated With Bone Metastasis/ Recurrence
In the analysis of local recurrence and distant recurrence at bone, lung, and other sites in TCGA, the patients with a high score were significantly more likely to experience bone metastasis (p = 0.0052) (Fig. 4a) . To confirm the predictive potential for bone recurrence, we compared the risk score based on the expression of the three miRNAs in primary breast tumor tissues from the patients who experienced bone recurrence in the course of the follow-up period (bone recurrence group, n = 10) and from the patients who never experienced any recurrence for more than 5 years after diagnosis (control breast cancer group, n = 10). The bone recurrence group showed a higher miRNA-based risk score than the control group, although TCGA data (n=1051) RNA-S eq with primary sample derived from independent cohort to validate predictive value of the score for bone recurrence.
FIG. 1
Study strategy for selecting a microRNA (miRNA) signature and generating risk scores to predict a poor prognosis. Patients from two representative overall survival groups, the long-survival group (those who survived longer than 5 years after diagnosis, n = 240) and the short-survival group (those deceased within 3 years after diagnosis, n = 65), were used to identify the top miRNAs with differential expression using a model implemented in the DEseq2 package based on the negative binomial distribution. First, the study identified as its candidates the top 19 miRNAs that showed the most different expression levels in the two groups (adjustment p value, \ 0.1). Next, highly related miRNA pairs (correlation, [ 0.85) were excluded to reduce the multicollinearity and improve stability for further model selection. Finally, using stepwise model selection based on the Akaike information criterion (AIC), the study identified the three-miRNAs risk score for the best multivariate Cox proportional hazard model of overall survival and their coefficients (miR-19a, miR-93, and miR-106a). The subject's risk scores were calculated using the three-miRNAs signature, and all the patients with The Cancer Genome Atlas (TCGA) breast cancer were classified into high risk-score/low risk-score groups. The same classification was used for the three independent validation data sets from METABRIC and GEO using these miRNAs 
FIG. 2
Overall and disease-free survival analyses using the multivariate Cox model and Kaplan-Meier curve for the threemiRNAs risk score in The Cancer Genome Atlas (TCGA) data set. a The patients with a high three-miRNAs risk score (n = 52) had a significantly poorer prognosis than the patients with a low score (n = 999) for overall survival (p = 0.0004) and disease-free survival
0001). Validation analyses for survival using three independent data sets (METABRIC cohort [c], GSE19536 [d], GSE22220 [e])
showed that the three-miRNAs risk score had a significant impact on patient survival in the three independent cohorts derived from the cBioPortal and GEO data sets (Fig. 4b) . The receiver operating characteristic (ROC) curve showed that the risk score could distinguish breast cancer patients who later had bone recurrence with relatively high diagnostic power (AUC, 0.71; sensitivity, 0.90; specificity, 0.65; accuracy 0.75) (Fig. 4c) .
Identification of Gene Sets Enriched with a High miRNA-Based Risk Score
To identify pathways and gene sets enriched with a miRNA-based risk score, GSEA was performed using RNA expression data from TCGA. The GSEA with hallmark gene sets (the most essential data set 34 ) showed that several pathways and gene sets critical for cancer tumorigenesis and progression were associated with the risk score. Of these, the angiogenesis (p \ 0.0001) and epithelial mesenchymal transition (EMT) (p = 0.0155) gene sets were the most significant ( Fig. 5a, b ; Tables S7,  S8 , and S9). In addition, the GSEA with C2 curated gene sets (including the KEGG and GO pathway gene sets) highlighted a number of pathways, including focal adhesion (p \ 0.0001), the transforming growth factor (TGF)-beta signaling pathway (p = 0.0025), the extracellular matrix (ECM) receptor interaction (p = 0.0068), and the mammalian target of rapamycin (mTOR) pathway (p = 0.0251), which are important for tumor progression, tumor invasion, or metastatic formation ( Fig. 5c-f ; Tables S10, S11, and S12). 
DISCUSSION
The current study developed and subsequently validated a composite risk score based on expression of three miRNAs with prognostic values for breast cancer independent of conventional clinical predictors. Further analyses demonstrated that the score was associated specifically with bone metastasis.
In the initial report of TCGA, 14 very few data were presented regarding miRNA expression profiles in breast cancer tissues. Clustering analysis of miRNA expression showed little correlation between miRNA subtype and mutation status except for two of the seven miRNA subsets overlapping with a basal-like subtype and showing a strong positive correlation with TP53 mutation and a negative correlation with PIK3CA and GATA3 mutations. 14 Several later studies explored miRNA expression patterns with breast cancer prognosis using a publically available TCGA data set. [35] [36] [37] [38] Volinia and Croce 35 identified a prognostic microRNA/mRNA signature using the TCGA data set and a validation cohort. However, they used only 247 miRNAs in 466 breast cancer samples, and the prognostic signature included 10 mRNAs and 2 miRNAs. Therefore, it was unclear whether the prognostic effects of the miRNAs were independent of mRNAs. Cumulative incidence rate analysis using the three-miRNAs risk score for each metastatic site (bone, n = 41; local recurrence, n = 15; lung, n = 12; other, n = 15). a Bone was associated significantly with a high three-miRNAs risk score. b The patients who experienced recurrent bone metastasis showed higher levels of the three-miRNAs risk score than the matched control patients who did not (control breast cancer group, n = 10; bone recurrence group, n = 10; p = 0.1847). c The receiver operating characteristic (ROC) curve using the three-miRNAs risk score derived from miRNA-Seq data of the 20 primary tissue samples showed an area under the curve (AUC) of 0.71, a sensitivity of 0.90, a specificity of 0.65, and an accuracy of 0.75
miR-Based Risk Score as Novel Biomarker in Breast Cancer
In another report by Zhou et al. 38 based on 915 patients from TCGA showed that a signature consisting of 14 miRNAs was prognostic for patients with ER-positive cancers, whereas the significance of the signature for other subtypes was unclear.
The most important limitations in these previous TCGAbased studies were that the clinical data were obtained before 2015 when follow-up data were integrated only in TCGA data sets, and that these studies relied solely on the TCGA cohort without independent validation cohorts. To overcome these limitations, we used the TCGA data set with the latest clinical information as the discovery cohort, followed by validation using independent cohorts from the METABRIC and GEO data sets, which had sufficient numbers of cases.
Each of the three miRNAs (miR-19a, miR-93, and miR106a) selected for our risk score is located in an miRNA cluster region, including the miR17-92 cluster in 13q31, the miR-106b-25 cluster in 7q22, and the miR-106a-363 cluster in Xq26, respectively. Previous reports have demonstrated that these clusters play critical roles in various cancers. 8, [39] [40] [41] miRNAs are frequently transcribed together as polycistronic primary transcripts processed into multiple individual mature miRNAs. 42, 43 The genomic organization of miRNA clusters often is highly conserved, suggesting that it may play biologically important roles for coordinated regulations and functions. For example, the miR-17-92 cluster encodes six miRNAs (miR-17, miR-18a, miR-19a, miR-20a, miR-19b, and miR-92), which are tightly located within an 800-bp region of human chromosome 13. Ancient gene duplications have given rise to two miR-17-92 cluster paralogs, the miR106b-25 cluster in chromosome 7 and the miR-106a-363 cluster in the X chromosome, both of which contain miRNAs homologous to a subset of miR-17-92 components. 43, 44 Previous reports showed the miR-17-92 cluster regulating multiple cellular processes and functions as a strong ''oncogene'' favoring malignant transformation and promoting cell survival, cell proliferation, and increased angiogenesis through critical molecules or a pathway such as c-MYC or TGFb signaling. 39, 40, 45, 46 In this regard, our result from GSEA analysis showing that a high risk score was in a significant association with angiogenesis or EMT is compatible with the reports described earlier.
Bone is the most frequent metastatic site in breast cancer, which remains an incurable disease. Therefore, novel prognostic biomarkers specific for bone recurrence of breast cancer, including the miRNA-based risk score we developed in this study, may improve risk assessment to guide adjuvant therapy, allowing patients with a high risk of bone recurrence to receive more aggressive follow-up assessment and/or more effective adjuvant therapy. The biomarkers also may identify early bone metastases.
Some studies have reported therapeutic potentials of the miRNAs we have used for the scoring. For example, miR106a can negatively regulate ZBTB4 expression, and overexpression or restoration of ZBTB4 by an antagomir of miR-106a inhibits growth and invasion of breast cancer. 47 Another report demonstrated that suppressed miR-19a expression upregulates Fra-1 expression and induces M2 macrophage polarization, and that miR-19a inhibits breast cancer progression and metastasis. 48 Together, these miRNAs can be potential therapeutic targets in addition to being diagnostic markers in breast cancer patients. Further investigation is warranted.
The current study had two major limitations. First, the follow-up data in TCGA seemed to be insufficient. We believe our methodology in the development of the miRNA-based risk score, using two distinct survivor groups (long-and short-term survivors), may emphasize the biologic feature that could have an impact on patient survival and overcome this limitation for the short followup assessment issue. Second, the score of the three miRNAs was derived from women who received the standard of care based on intrinsic subtype and stage. This study could not discern whether it is only a general prognostic marker or also a predictive marker for response to treatment.
Although the aforementioned limitations should be recognized, we believe the current study is in line with the important concept of ''building bridges between basic and clinical genomic research'' in translational research, which has been stressed recently in some commentaries. [49] [50] [51] It is a good example of using a bioinformatics approach with established large cohorts to clarify the clinical relevance of genomic and/or epigenomic biomarkers. As has been emphasized by many, the use of big data is expected to become a common method of analyses in very near future.
In conclusions, on the basis of unbiased integrated analysis using large publically available cohorts, we identified a promising risk score based on three miRNAs in primary breast cancer for prognosis of survival outcomes and bone metastasis. Using this score may allow for more aggressive intervention or intensive follow-up treatment tailored for patients at high risk after their initial breast cancer diagnosis.
